E. Crucitta

657 total citations
22 papers, 532 citations indexed

About

E. Crucitta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E. Crucitta has authored 22 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in E. Crucitta's work include Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (5 papers). E. Crucitta is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (5 papers). E. Crucitta collaborates with scholars based in Italy and United States. E. Crucitta's co-authors include M. De Lena, Michele Guida, Agnese Latorre, Vito Lorusso, D. Sambiasi, Annamaria Catino, Antonella Mazzei, G Gargano, Giuseppe Fanizza and Vito Lorusso and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

E. Crucitta

21 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Crucitta Italy 11 194 137 128 96 84 22 532
Merry Tetef United States 14 269 1.4× 82 0.6× 147 1.1× 118 1.2× 78 0.9× 29 581
Luis T. Campos United States 13 441 2.3× 61 0.4× 201 1.6× 140 1.5× 26 0.3× 29 726
Filomena Del Gaizo Italy 10 188 1.0× 134 1.0× 95 0.7× 32 0.3× 87 1.0× 20 423
Mohammad R. Nowrousian Germany 15 237 1.2× 359 2.6× 245 1.9× 34 0.4× 114 1.4× 31 693
Phb Willemse Netherlands 13 279 1.4× 71 0.5× 96 0.8× 44 0.5× 18 0.2× 32 483
Keith D. Jones Canada 5 125 0.6× 146 1.1× 35 0.3× 40 0.4× 43 0.5× 6 441
Patrick Johnston United Kingdom 12 460 2.4× 48 0.4× 206 1.6× 92 1.0× 20 0.2× 21 704
F Turpin France 10 247 1.3× 39 0.3× 85 0.7× 85 0.9× 42 0.5× 35 410
N P Bailey United Kingdom 11 266 1.4× 129 0.9× 90 0.7× 28 0.3× 58 0.7× 18 496
A Krikorian France 13 538 2.8× 37 0.3× 174 1.4× 63 0.7× 73 0.9× 13 674

Countries citing papers authored by E. Crucitta

Since Specialization
Citations

This map shows the geographic impact of E. Crucitta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Crucitta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Crucitta more than expected).

Fields of papers citing papers by E. Crucitta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Crucitta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Crucitta. The network helps show where E. Crucitta may publish in the future.

Co-authorship network of co-authors of E. Crucitta

This figure shows the co-authorship network connecting the top 25 collaborators of E. Crucitta. A scholar is included among the top collaborators of E. Crucitta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Crucitta. E. Crucitta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cappuzzo, Federico, Silvia Novello, Filippo de Marinis, et al.. (2005). Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. British Journal of Cancer. 93(1). 29–34. 27 indexed citations
2.
Marco, Vincenzo De, Filomena Longo, Francesco Pinto, et al.. (2005). Pharmacokinetic Study of Intravesical Gemcitabine in Carcinoma in situ of the Bladder Refractory to Bacillus Calmette-Guérin Therapy. Urologia Internationalis. 75(4). 309–313. 19 indexed citations
3.
4.
Lorusso, Vito, E. Crucitta, Nicola Silvestris, et al.. (2005). Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.. PubMed. 13(2). 283–7. 19 indexed citations
5.
Silvestris, Nicola, Modesto DʼAprile, Giovanna Andreola, et al.. (2004). Rationale for the use of gemcitabine in breast cancer (Review). International Journal of Oncology. 24(2). 389–98. 11 indexed citations
6.
Lorusso, Vito, E. Crucitta, Nicola Silvestris, et al.. (2003). Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. British Journal of Cancer. 88(4). 491–495. 9 indexed citations
7.
Lorusso, Vito, E. Crucitta, Nicola Silvestris, et al.. (2003). A Phase I Study of Capecitabine in Combination with Vinorelbine in Advanced Breast Cancer. Clinical Breast Cancer. 4(2). 138–141. 20 indexed citations
8.
Silvestris, Nicola, et al.. (2003). Unusual Response to Second-Line Single-Agent Gemcitabine in Locally Advanced Primary Leiomyosarcoma of the Lung: A Case Report. Journal of Chemotherapy. 15(5). 507–509. 7 indexed citations
9.
Catino, Annamaria, et al.. (2003). Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. Oncology Reports. 10(1). 163–7. 5 indexed citations
10.
Cappuzzo, Federico, Silvia Novello, Filippo de Marinis, et al.. (2003). 793 Multicenter phase II study of gemcitabine-oxaliplatin (GEMOX) chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) patients. European Journal of Cancer Supplements. 1(5). S238–S238. 1 indexed citations
11.
Lorusso, Vito, E. Crucitta, N. Panza, et al.. (2002). Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer. Annals of Oncology. 13(12). 1862–1867. 4 indexed citations
12.
13.
Crucitta, E., et al.. (2002). AIDS-related non-Hodgkin's lymphoma: Clinico-pathological characteristics and therapeutic strategies (Review). International Journal of Oncology. 20(3). 611–5. 4 indexed citations
14.
Comella, P., Rossana Casaretti, E. Crucitta, et al.. (2002). Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. British Journal of Cancer. 86(12). 1871–1875. 21 indexed citations
15.
Guida, Michele, et al.. (2002). Metastatic malignant melanoma of the gallbladder. Melanoma Research. 12(6). 619–625. 33 indexed citations
16.
Latorre, Agnese, M. De Lena, Annamaria Catino, et al.. (2002). Epithelial ovarian cancer: Second and third line chemotherapy (Review). International Journal of Oncology. 21(1). 179–86. 27 indexed citations
17.
Crucitta, E.. (2001). The role of letrozole (Femara(R)) in breast cancer therapy: Aclinical review. Drugs of today. 37(9). 639–639. 4 indexed citations
18.
Lena, M. De, Vito Lorusso, Agnese Latorre, et al.. (2001). Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. European Journal of Cancer. 37(3). 364–368. 150 indexed citations
19.
Comella, P., Ferdinando De Vita, Lucia Liguori, et al.. (2001). Biweekly irinotecan (IRI) with 6s-folinic acid (FA)-modulated 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC): a phase III study. European Journal of Cancer. 37. S302–S302. 1 indexed citations
20.
Crucitta, E., et al.. (2000). New aromatase inhibitors in the treatment of advanced breast cancer.. International Journal of Oncology. 17(5). 1037–41. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Merry Tetef Breakdown of academic impact, for papers by Luis T. Campos Breakdown of academic impact, for papers by Filomena Del Gaizo Breakdown of academic impact, for papers by Mohammad R. Nowrousian Breakdown of academic impact, for papers by Phb Willemse Breakdown of academic impact, for papers by Keith D. Jones Breakdown of academic impact, for papers by Patrick Johnston Breakdown of academic impact, for papers by F Turpin Breakdown of academic impact, for papers by N P Bailey Breakdown of academic impact, for papers by A Krikorian
Rankless by CCL
2026